(See LPTX stock analysis on TipRanks) Corvus Pharmaceuticals (CRVS) Focused on the development of medicines with precise mechanisms of action, Corvus Pharmaceuticals wants to improve the lives of patients with difficult-to-treat cancers like refractory renal cell carcinoma and non-small cell lung cancer. On July 7, CRVS unveiled an additional clinical program for CPI-006, its patented monoclonal antibody targeting CD73, and initiated a Phase 1 study to evaluate the drug in COVID-19 patients. So, CRVS gets a unanimous Strong Buy consensus rating.